Last reviewed · How we verify
chemoprevention
chemoprevention is a Small molecule drug developed by Ohio State University Comprehensive Cancer Center. It is currently in Phase 1 development. Also known as: cancer chemoprevention, chemoprevention of cancer.
Chemoprevention is the administration of a medication to prevent disease or infection, as seen in the use of antibiotics to prevent bacterial infections in individuals with weakened immune systems. Chemoprevention has been studied in various conditions, including vulvar cancer, malaria, tuberculosis, and bladder carcinoma, using interventions such as ciclopirox and the PfSPZ vaccine.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | chemoprevention |
|---|---|
| Also known as | cancer chemoprevention, chemoprevention of cancer |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (PHASE2)
- Post-exposure Influenza Prophylaxis (PHASE3)
- Testing for Safety and Colorectal Cancer Preventive Effects of ONC201 (PHASE1)
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment (PHASE2)
- Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty (PHASE2)
- Leveraging the Seasonal Malaria Chemoprevention Platform to Address Malaria and Malnutrition (NA)
- Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers (PHASE2)
- PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chemoprevention CI brief — competitive landscape report
- chemoprevention updates RSS · CI watch RSS
- Ohio State University Comprehensive Cancer Center portfolio CI
Frequently asked questions about chemoprevention
What is chemoprevention?
Who makes chemoprevention?
Is chemoprevention also known as anything else?
What development phase is chemoprevention in?
Related
- Manufacturer: Ohio State University Comprehensive Cancer Center — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: cancer chemoprevention, chemoprevention of cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing